# ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--dc394a6b
Ticker: ORIC
Company: Oric Pharmaceuticals, Inc.
Source: Oric Pharmaceuticals, Inc.
Published: 2026-07-02 20:30 EST
Original Source URL: https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-33
## Summary

SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted

## Article Body
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted
## Recent Company News
- 2026-07-02 20:30 EST — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--dc394a6b) — Source: Oric Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Oric Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates](https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-updates) — Source: Oric Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting](https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-announces-preclinical-rinzimetostat-oric-944-presentations-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting) — Source: Oric Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC](https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-to-report-combination-dose-optimization-data-from-phase-1b-trial-of-rinzimetostat-in-patients-with-mcrpc) — Source: Oric Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)